Lithium

Lithium

SCHEMBL7180601

COc1ccc(PC(=O)c2c(C)cc(C(C)(C)C)cc2C)c(OC)c1.[Li]

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
LPAR1 Q92633 1/20 0.38
MAPT P10636 5/20 0.37
GAA P10253 2/20 0.37
KDM4E B2RXH2 1/20 0.37
PKM P14618 1/20 0.37
MEN1 O00255 2/20 0.37
NR1I2 O75469 4/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 4/20 0.36
LMNA P02545 1/20 0.36
ALOX15 P16050 1/20 0.36
APEX1 P27695 1/20 0.36
MAPK1 P28482 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180594 0.97 KMT2A (0.39) KMT2ALPAR1MAPTGAAKDM4E
Lithium SCHEMBL7182503 0.88 KMT2A (0.41) KMT2AMAPTGAAKDM4EPKM
SCHEMBL7189379 0.87 MAPT (0.38) KMT2AMAPTMEN1NR1I2NPC1
Lithium SCHEMBL7188548 0.85 KMT2A (0.45) KMT2AMAPTGAAMEN1NPC1
SCHEMBL7182499 0.85 KMT2A (0.41) KMT2AMAPTGAAKDM4EPKM
Lithium SCHEMBL7181217 0.84
Lithium SCHEMBL7186950 0.83 KMT2A (0.39) KMT2AMAPTGAAKDM4EPKM
SCHEMBL7188541 0.83 KMT2A (0.45) KMT2AMAPTGAAMEN1NPC1
Lithium SCHEMBL7187691 0.82 NR1H4 (0.39) KMT2AMAPTKDM4EALDH1A1HSD17B10
Lithium SCHEMBL7188278 0.82 KMT2A (0.51) KMT2AMAPTGAAMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885LPAR1 499/4885MAPT 4870/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885LPAR1 536/4885MAPT 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.